Can a transplant drug stop COVID lung damage?
NCT ID NCT04948203
First seen Jan 06, 2026 · Last updated May 25, 2026 · Updated 18 times
Summary
This study tests whether sirolimus, a drug used to prevent organ rejection, can reduce the risk of lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults will receive sirolimus to see if it prevents long-term lung damage. The goal is to improve recovery and reduce complications like long COVID.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.